Klinikum Darmstadt GmbH — Clinical Trial Site

38 Registered trials

15 Currently recruiting

Organisation

Klinikum Darmstadt GmbH

Location

Darmstadt, Germany

Identifier

ORG-100033067

Address

Grafenstrasse 9, 64283, Germany

Departments

#40288: Dermatology
3106: Dermatology
9170: Dermatology
Department of Dermatology
Department of Oncology and Hematology (Med. Klinik V)
Dermatology
Dermatology Department
Frauenklinik
Hautklinik
Hematology
Institut für Radioonkologie und Strahlentherapie
Klinikum Darmstadt GmbH
Klinikum Darmstadt GmbH Medizinische Klinik V - Hämatologie, Onkologie und Palliativmedizin
Med. Klinik II
Medizinische Klinik II
Medizinische Klinik II-Gastroenterologie, Hepatopankreatologie, Diabetologie und Pneumonie
Medizinische Klinik V
Medizinische Klinik V - Hämatologie, Onkologie und Palliativmedizin
Medizinische Klinik V - Onkologie und Hämatologie
Medizinische Klinik V / Haematologie
Medizinische Klinik V Hämatologie / Onkologie
N/A
NA

Clinical trials at this site (38)

Search interface

A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD-… Recruiting

2024-520264-33-00 Locoregionally recurrent head and neck squamous cell ca 5 2025-10-07
Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting

2024-517632-22-00 Hidradenitis Suppurativa 5 2025-10-06
A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Recruiting

2024-519736-17-00 Hidradenitis Suppurativa 4 2025-10-03
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 4 2023-08-28
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal C… Ended

2024-513914-36-00 locally-advanced Anal Carcinoma, Anal cancer stage II a 4 2019-12-17